Skip to main content

Determinants of Progression in Early Breast and Ovarian Cancer

Scientific Focus

Research efforts led by Jeffrey Marks, PhD, and E. Shelley Hwang, MD, MPH, focus on the earliest stages of breast cancer. Working at the center of multi-institutional and multi-disciplinary projects on the disease, the Marks-Hwang laboratory studies the genetics, microenvironment, and evolution of early breast cancer. We are studying primary human ductal carcinoma in situ (DCIS) lesions that have not progressed to invasive cancer and comparing these to lesions that have progressed to invasive and metastatic disease. Our central hypothesis regarding progression is that principles of evolution applied to human cancer can help to predict which lesions should be aggressively treated from those that are indolent and unlikely to progress. 

To test this, we are pushing next-generation sequencing to the current technologic limits to derive broad exome-based DNA analysis to measure variant alleles and copy number changes that underlie the genetic and phenotypic heterogeneity of the disease. In parallel, we are also measuring parameters of the microenvironment as additional driving forces in tumor evolution. Our goal is to combine the most informative elements that define heterogeneity into a practical tool that can accurately predict the likelihood of progression. 

The lab has focused on highly multi-disciplinary projects incorporating quantitative, population, genetic, and behavioral approaches. Given the heterogeneity of human beings and the cancers that arise in them, it is essential to balance and validate insights gained from in vitro approaches and model systems with the actual primary disease states. Fully embracing this heterogeneity and complexity towards incorporating it into clinical practice constitutes the next major challenge our lab seeks to explore in cancer research. 

Dr. Marks is a Ph.D. basic/translational scientist who has investigated numerous aspects of breast and ovarian cancer since joining the faculty of the Department of Surgery in 1988. Dr. Hwang is a breast cancer surgeon and translational researcher who has been at Duke since 2011. These two investigators have common interests in studying cancer progression of DCIS, an increasingly common diagnosis that is not invasive at the time of presentation but carries a measurable risk of invasive progression. Treatment for this proliferative breast condition ranges from a watchful waiting approach to bilateral mastectomy. Therefore, in addition to the biologic relationship between DCIS and invasive cancer, the broad range of treatments that are considered appropriate makes this disease of great scientific interest and fundamental importance. The lab is highly interdisiciplinary and integrates scientific collaborators from UCSF, OHSU, Stanford University, USC, and member institutions of the TBCRC, a clinical trials translational research network.

Contact Us

Jeffrey R. Marks, PhD
Jeff.marks@duke.edu

Shelley Hwang, MD, MPH
Shelley.hwang@duke.edu

Lorraine King, PhD
Lorraine.king@duke.edu

Latest Publications

Shi, B, Grimm, LJ, Mazurowski, MA, Baker, JA, Marks, JR, King, LM, Maley, CC, Hwang, ES, and Lo, JY. "Prediction of Occult Invasive Disease in Ductal Carcinoma in Situ Using Deep Learning Features." Journal of the American College of Radiology : JACR 15, no. 3 Pt B (March 2018): 527-534.

Full Text

Keene, KS, King, T, Hwang, ES, Peng, B, McGuire, K, Tapia, C, Zhang, H, Bae, S, Nakhlis, F, Klauber-Demore, N, Meszoely, I, Sabel, MS, Willey, SC, Eterovic, KA, Hudis, C, Wolff, A, De Los Santos, J, Thompson, A, Mills, GB, and Meric-Bernstam, F. "Molecular determinants of post-mastectomy breast cancer recurrence." February 2018.

Scholars@Duke

Rosenberg, SM, Gierisch, JM, Lowenstein, C, Frank, ES, Collyer, D, Partridge, AH, and Hwang, ES. "Is it cancer or not? A qualitative exploration of patient perspectives surrounding the diagnosis and treatment of DCIS." February 2018.

Scholars@Duke

Ryser, MD, Weaver, DL, Marks, JR, Hyslop, T, and Hwang, ES. "Quantifying the natural history and overtreatment rate of ductal carcinoma in situ." February 2018.

Scholars@Duke